In addition, antiangiogenic therapies can induce the systemic upregulation of off-target molecules such as osteopontin and G-CSF and thereby increase the extravasation potential of tumor cells or support the pre-metastatic niche. This evidence concerns the gene CSF3 and neoplasm.